148 related articles for article (PubMed ID: 17388918)
1. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
Meier F; Busch S; Lasithiotakis K; Kulms D; Garbe C; Maczey E; Herlyn M; Schittek B
Br J Dermatol; 2007 Jun; 156(6):1204-13. PubMed ID: 17388918
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Lasithiotakis KG; Sinnberg TW; Schittek B; Flaherty KT; Kulms D; Maczey E; Garbe C; Meier FE
J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
[TBL] [Abstract][Full Text] [Related]
3. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
4. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways.
Matsuoka H; Tsubaki M; Yamazoe Y; Ogaki M; Satou T; Itoh T; Kusunoki T; Nishida S
Exp Cell Res; 2009 Jul; 315(12):2022-32. PubMed ID: 19393235
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and mitogenic effects of IGF-II in rainbow trout (Oncorhynchus mykiss) myocytes in culture and the role of IGF-II in the PI3K/Akt and MAPK signalling pathways.
Codina M; García de la serrana D; Sánchez-Gurmaches J; Montserrat N; Chistyakova O; Navarro I; Gutiérrez J
Gen Comp Endocrinol; 2008 Jun; 157(2):116-24. PubMed ID: 18504044
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
9. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
10. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
11. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
12. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
Wang J; Zhao Y; Kauss MA; Spindel S; Lian H
Eur J Cell Biol; 2009 Feb; 88(2):103-15. PubMed ID: 19058874
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium bovis Bacillus Calmette-Guérin (BCG) stimulates IL-10 production via the PI3K/Akt and p38 MAPK pathways in human lung epithelial cells.
Méndez-Samperio P; Trejo A; Pérez A
Cell Immunol; 2008 Jan; 251(1):37-42. PubMed ID: 18423589
[TBL] [Abstract][Full Text] [Related]
14. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro.
Lissitzky JC; Parriaux D; Ristorcelli E; Vérine A; Lombardo D; Verrando P
Cancer Res; 2009 Feb; 69(3):802-9. PubMed ID: 19176384
[TBL] [Abstract][Full Text] [Related]
15. Effect of 2-hydroxyethyl methacrylate on human pulp cell survival pathways ERK and AKT.
Spagnuolo G; D'Antò V; Valletta R; Strisciuglio C; Schmalz G; Schweikl H; Rengo S
J Endod; 2008 Jun; 34(6):684-8. PubMed ID: 18498889
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Sinnberg T; Lasithiotakis K; Niessner H; Schittek B; Flaherty KT; Kulms D; Maczey E; Campos M; Gogel J; Garbe C; Meier F
J Invest Dermatol; 2009 Jun; 129(6):1500-15. PubMed ID: 19078992
[TBL] [Abstract][Full Text] [Related]
17. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
18. B-RAF is a therapeutic target in melanoma.
Karasarides M; Chiloeches A; Hayward R; Niculescu-Duvaz D; Scanlon I; Friedlos F; Ogilvie L; Hedley D; Martin J; Marshall CJ; Springer CJ; Marais R
Oncogene; 2004 Aug; 23(37):6292-8. PubMed ID: 15208680
[TBL] [Abstract][Full Text] [Related]
19. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma.
Hersey P
Curr Opin Oncol; 2006 Mar; 18(2):189-96. PubMed ID: 16462190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
